The groups have also invested in antimalaria drugs for A.C.T., artemisinin-based combination therapy.
这些组织也投资于抗疟疾药物开发，基于青蒿素的组合疗法。
Which patients might be particularly suitable for olmesartan-based combination therapy?
哪些患者可能尤其适合基于奥美沙坦的联合治疗？
Although patients infected were cured following treatment with an artemisinin-based combination therapy (ACT), the recovery took more time.
虽然感染患者在接受以青蒿素为基础的联合化疗之后痊愈，但恢复时间较长。
"WHO has provide diagnostic kits, artemisinin-based combination therapy and other malaria treatment for the population in need," said Chaib.
沙伊布说：“世卫组织已经为有需要的民众提供了诊断器具、以青蒿素为基础的综合治疗及其它治疟疾的药物。”
Critics of the Lasker citation emphasize that development of the artemisinin-based combination therapy used today resulted from a scientific relay race that went through many stages.
拉斯克奖的批评者强调，如今使用的基于青蒿素的组合疗法是一个科学接力赛的产物，经过了许多阶段。
In recent years a new type of treatment called artemisinin-based combination therapy (ACTs) has transformed the treatment of malaria, but if not used properly the medicine could become ineffective.
近些年来，一种称为青蒿素为基础的联合疗法(ACTs)的新型治疗方法对疟疾的治疗带来了转变。但是，如果使用不当，该药品会变得无效。
Of the 42 malaria-endemic countries in the African Region, 33 have adopted artemisinin-based combination therapy — the most effective antimalarial medicines available today — as first-line treatment.
在非洲区域42个疟疾流行国中，有33个已经采用了以青蒿素为基础的合并疗法，它是作为一线治疗的目前最有效的抗疟药物。
Research released by the Massachusetts Institute of Technology describes an adhesive patch that can deliver a triple-combination of drug, gene, and light-based therapy to colorectal tumors.
由麻省理工学院发布的研究成果表明用一种能够提供药物、基因和光疗三联疗法的贴片可以用来治疗结肠癌。
In late February 2016, the FDA approved the anti-CD20 agent obinutuzumab(Gazyva) in combination with bendamustine for patients with follicular lymphoma following rituximab-based therapy.
2016年2月底，FDA批准了对接受过利妥昔单抗治疗的滤泡性淋巴瘤患者使用抗CD20单抗obinutuzumab和苯达莫司汀联合的方案。
In late February 2016, the FDA approved the anti-CD20 agent obinutuzumab(Gazyva) in combination with bendamustine for patients with follicular lymphoma following rituximab-based therapy.
2016年2月底，FDA批准了对接受过利妥昔单抗治疗的滤泡性淋巴瘤患者使用抗CD20单抗obinutuzumab和苯达莫司汀联合的方案。
应用推荐